Physiologically‐based pharmacokinetic modeling of the drug-drug interaction between ivacaftor and lefamulin in cystic fibrosis patients

• 主要な著者: Magali Amiel (著者), Alice Ke (著者), Steven P. Gelone (著者), Hannah M. Jones (著者), Wolfgang Wicha (著者)
• フォーマット: 図書
• 出版事項: Wiley, 2024-04-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Abstract Lefamulin is being evaluated as a treatment for bacterial exacerbations in cystic fibrosis (CF). Ivacaftor is approved for the treatment of patients with CF. Lefamulin is a moderate CYP3A inhibitor and co‐administration with ivacaftor may result in a drug-drug interaction (DDI). A CF popula...